RSS-Feed abonnieren
DOI: 10.1055/s-0030-1262710
© Georg Thieme Verlag KG Stuttgart ˙ New York
Klinische Studien zu Exenatide 1 × wöchentlich – Ein neuer, einmal wöchentlicher GLP-1-Rezeptoragonist zur Verbesserung der Therapie des Typ-2-Diabetes
Clinical Studies of Exenatide Once Weekly, a Novel, Once Weekly GLP-1 Receptor Agonist for Improved Management of Type 2 DiabetesPublikationsverlauf
Publikationsdatum:
20. Dezember 2010 (online)

Zusammenfassung
Exenatide 1 × wöchentlich (Exenatide QW) ist eine neue Formulierung des Wirkstoffs Exenatide, die durch eine Mikrospheren-Technologie ein sehr langsames Anfluten durch ein langsam biodegradierbares Polymer, das als Träger von Exenatide fungiert, ermöglicht. Dadurch ändern sich sowohl das Wirkungs- als auch das Nebenwirkungsprofil im Vergleich zur kurzwirksamen Rezeptorstimulation mit herkömmlichem Exenatide. Studien konnten eine stärkere Senkung der Nüchternblutzuckerwerte und des HbA1c durch Dauerstimulation am GLP-1-Rezeptor zeigen. Mit Metformin als Basistherapie führte Exenatide QW zu einer überlegenen mittleren HbA1c-Senkung von 1,5 % bzw. 1,9 %, im Vergleich zu Exenatide 2 × tgl. (HbA1c – 1,0 %), Sitagliptin (HbA1c – 0,9 %), Pioglitazon (HbA1c – 1,2 %) oder Insulin Glargin (HbA1c – 1,3 %). Aufgrund einer geringeren Hemmwirkung auf die Magenentleerung ist dagegen die postprandiale Glukoseabsenkung etwas weniger ausgeprägt als unter herkömmlichem Exenatide, dafür ist die gastrointestinale Nebenwirkungsrate um etwa ⅓ (20 % versus 35 %) geringer. Zusätzlich wurde in allen Studien eine relevante mittlere Gewichtsabnahme erreicht (von – 2,3 bis – 3,7 kg). Darüber hinaus konnten positive Effekte auf den Blutdruck, das Lipidprofil und andere kardiovaskuläre Risikofaktoren beobachtet werden. Deshalb ist eine kardiovaskuläre Outcome-Studie angelaufen, deren Daten in den nächsten Jahren zu erwarten sind. Die bisherigen klinischen Studiendaten belegen, dass Exenatide QW eine nützliche Therapieoption bei übergewichtigen, schlecht eingestellten Patienten mit Typ-2-Diabetes nach Metformin darstellt, wenngleich sich Exenatide QW noch im klinischen Alltag und in Langzeitstudien bewähren muss.
Abstract
Exenatide once weekly (exenatide QW) is a new dosage form of the active drug exenatide. Exenatide QW’s microsphere technology enables very slow release due to the use of a slowly biodegradable polymer as the exenatide carrier. This changes both the effect and adverse effect profiles versus the short-acting receptor stimulation produced by exenatide two times daily. Long-term stimulation of GLP-1 receptors results in superior lowering of fasting blood glucose levels and HbA1c. In subjects on first-line treatment with metformin, exenatide QW produced superior HbA1c reduction, with mean HbA1c reductions of 1.5–1.9 % versus exenatide two times daily (HbA1c – 1.0 %), sitagliptin (HbA1c – 0.9 %), pioglitazone (HbA1c – 1.2 %) and insulin glargine (HbA1c – 1.3 %). Because of the less pronounced inhibition of gastric emptying, postprandial glycemia reduction is somewhat less effective than with conventional exenatide. Against that, gastrointestinal toxicity is reduced by about one-third (20 % versus 35 %). In addition, a relevant loss in mean weight (ranging from 2.3 to 3.7 kg) was seen in all studies. Benefits were also documented for blood pressure, lipid profiles and other cardiovascular risk factors. A cardiovascular outcome study has been launched which is expected to generate data within the next few years. Clinical study data available to date show that exenatide QW is a useful therapeutic option in subjects with poorly controlled type 2 diabetes on metformin, even though the value of exenatide QW has not yet been proven in real-life clinical practice and in long-term studies.
Schlüsselwörter
Exenatide - Exenatide QW - GLP-1-Rezeptoragonist - inkretinbasierte Therapie - Typ-2-Diabetes-Therapie
Key words
exenatide - exenatide QW - GLP-1 receptor agonist - incretin based therapy - type 2 diabetes therapy
Literatur
- 1 Drucker D J, Sherman S I, Gorelick F S et al. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010; 33 428-433
- 2 Rachman J, Barrow B A, Levy J C et al. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997; 40 205-211
- 3 Linnebjerg H, Park S, Kothare P A et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008; 151 123-129
- 4 Drucker D J, Buse J B, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008; 372 1240-1250
- 5 Buse J B, Drucker D J, Taylor K L et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010; 33 1255-1261
- 6 Juhl C B, Hollingdal M, Sturis J et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002; 51 424-429
- 7 Degn K B, Juhl C B, Sturis J et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004; 53 1187-1194
- 8 Buse J B, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374 39-47
- 9 Meier J J, Gallwitz B, Schmidt W E et al. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol. 2002; 440 269-279
- 10 Wang G J, Tomasi D, Backus W et al. Gastric distention activates satiety circuitry in the human brain. Neuroimage. 2008; 39 1824-1831
- 11 Eldridge J H, Staas J K, Tice T R et al. Biodegradable poly(DL-lactide-co-glycolide) microspheres. Res Immunol. 1992; 143 557-563
- 12 Kim D, Macconell L, Zhuang D et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007; 30 1487-1493
- 13 Belvins T, Pullman J, Malloy J et al. DURATION-5: Exenatide once weekly resulted in significantly greater Improvement in glycemic control with less nausea than Exenatide twice daily in patients with type 2 diabetes. Diabetes. 2010; 59 (Supplement 1) 8lb
- 14 Bergenstal R M, Wysham C, Macconell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010; 376 431-439
- 15 Wysham C, Bergenstal R, Malloy J et al. DURATION: Effect of switching to once-weekly Exenatide from maximum daily doses of Sitagliptin or Pioglitazon. Diabetes. 2010; 59 (Supplement 1) 594
- 16 Diamant M, Van G L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010; 375 2234-2243
- 17 Franciosi M, Pellegrini F, De B G et al. The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patients: an urgent need for better educational strategies. Diabetes Care. 2001; 24 1870-1877
- 18 Best J H, Boye K S, Rubin R R et al. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med. 2009; 26 722-728
- 19 Bruce S, Han J, Brown D C et al. Safety and tolerability of exenatide once weekly pooled summary of 1095 patients from DURATION-1, -2 and -3. Diabetes. 2010; 59 (Supplement 1) 61-OR
Dr. A. Haupt
Lilly Deutschland GmbH
Werner-Reimers-Str. 2–4
61352 Bad Homburg
Telefon: 00 49 / 61 72 / 2 73 21 74
Fax: 00 49 / 61 72 / 2 73 27 26
eMail: haupt_axel@lilly.com